Ademi LLP is investigating whether Renovacor, Inc. received a fair price in its transaction with Rocket Pharmaceuticals, Inc.

MILWAUKEE, September 21, 2022 /PRNewswire/ — Ademi LLP is investigating Renovacor (NYSE: RCOR) for possible breaches of fiduciary duty and other violations of law in its transaction with Rocket Pharmaceuticals.

Click here to find out how to join the action: or call Gouri Ademi toll free at 866-264-3995. There is no cost or obligation for you.

Ademi LLP alleges that Renovacor’s financial outlook and prospects are excellent and yet Renovacor holders will only receive $2.60 per share, based on the volume-weighted average trading price of Rocket shares of $15.51 for the 30 trading days up to and including Monday, September 19, 2022. The settlement agreement unreasonably limits competing offers for Renovacor by imposing a significant penalty if Renovacor accepts a superior offer. Renovacor insiders will receive substantial benefits under the Change of Control Agreements.

We are investigating the conduct of Renovacor’s board of directors and whether it (i) is fulfilling its fiduciary duties to all shareholders and (ii) obtaining a fair and reasonable price for Renovacor.

If you hold Renovacor common stock and would like additional information, please contact Gouri Ademi either at [email protected] or toll free: 866-264-3995, or

We specialize in shareholder disputes involving takeovers, mergers and individual shareholder rights nationwide. For more information, do not hesitate to call us. Lawyer advertisement. Prior results do not guarantee similar results.


Ademi LLP
Gouri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001


Comments are closed.